REGN 8-K 2026-01-12

REGENERON PHARMACEUTICALS, INC. (REGN) 8-K dated 2026-01-12 — accession 0001104659-26-002691. This URL is the filing, not the REGN hub.

REGENERON PHARMACEUTICALS, INC. (REGN) is a biotechnology company listed on US. It is led by Leonard S. Schleifer M.D., Ph.D..

REGENERON PHARMACEUTICALS, INC. filed a 8-K on 2026-01-12. Accession 0001104659-26-002691.

Cached items: 2.02, 7.01, 9.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 19.9.

Not investment advice. The REGN SEC hub lists recent forms. The stock page is the research view.